AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26801483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) therapy using tryptophan column
Number of subjects: 40
Study 24708773 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games with education and consultations for the family
Number of subjects: 40
Study 24708773 — intervention group
Group type: COMPARATOR
Intervention: General recommendation for physical activity for 30 minutes per day (Control)
Number of subjects: 40
Study 24708773 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games
Number of subjects: 40
Study 22513514 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T optimized protocol (triple dose of Gd, 20 min scan delay)
Number of subjects: 14
Study 22513514 — intervention group
Group type: COMPARATOR
Intervention: 1.5T standard protocol (single dose of Gd, 5 min scan delay)
Number of subjects: 14
Study 22513514 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 14
Study 20419359 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 434
Study 20419359 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study 18590111 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-IF-gamma
Number of subjects: 55
Study 18590111 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-TNF-alpha
Number of subjects: 55
Study 18590111 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 16096304 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing at home by specially trained midwives
Number of subjects: 762
Study 16096304 — intervention group
Group type: COMPARATOR
Intervention: Standard health promotion information (Control)
Number of subjects: 762
Study 12051282 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% diclofenac (Group A)
Number of subjects: 58
Study 12051282 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.1% dexamethasone (Group B)
Number of subjects: 58
Study 9925130 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microgram folic acid/d for 4 weeks
Number of subjects: 144
Study 9925130 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microgram folic acid/d for 4 weeks
Number of subjects: 144
Study 9925130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 7773216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 20
Study 7773216 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 20
Study 2245544 — intervention group
Group type: EXPERIMENTAL
Intervention: Core decompression
Number of subjects: 55
Study 2245544 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 55
Study 7433477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of methylglucamine indomethacinate (average dose 72.6 mg)
Number of subjects: 106
Study 7433477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of methylglucamine indomethacinate (average dose 36.1 mg)
Number of subjects: 106
Study 30176093 — intervention group
Group type: EXPERIMENTAL
Intervention: NCES prepared by 4C method
Number of subjects: 30
Study 30176093 — intervention group
Group type: COMPARATOR
Intervention: lab‐NCES
Number of subjects: 30
Study 26646593 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application + health coach intervention and counseling sessions
Number of subjects: 62
Study 26646593 — intervention group
Group type: COMPARATOR
Intervention: Control condition with a counseling session
Number of subjects: 62
Study 26672982 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic images plus text
Number of subjects: 293
Study 26672982 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic images with elaborated text
Number of subjects: 293
Study 26672982 — intervention group
Group type: COMPARATOR
Intervention: Text only
Number of subjects: 293
Study 26672982 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic images
Number of subjects: 293
Study 23337440 — intervention group
Group type: EXPERIMENTAL
Intervention: Laplace (double-exponential) distribution
Number of subjects: 0
Study 23337440 — intervention group
Group type: EXPERIMENTAL
Intervention: Image contrast
Number of subjects: 0
Study 22321682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular tissue matrix patch during Lichtenstein herniorrhaphy
Number of subjects: 60
Study 22321682 — intervention group
Group type: COMPARATOR
Intervention: Traditional high ligation of hernial sac
Number of subjects: 60
Study 19556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 14703
Study 19556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 14703
Study 19556260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier estimated rate of GI bleeding at 6 months
Number of subjects: 14703
Study 17493498 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding allergenic triggers
Number of subjects: 0
Study 17493498 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely administration of epinephrine
Number of subjects: 0
Study 17493498 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental medications
Number of subjects: 0
Study 15361183 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant platinum chemotherapy
Number of subjects: 463
Study 15361183 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal radiotherapy (in one randomized group)
Number of subjects: 463
Study 11133793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anterior parietal lobe lesions
Number of subjects: 22
Study 11133793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with posterior parietal lesions
Number of subjects: 22
Study 11133793 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with frontal lobe lesions
Number of subjects: 22
Study 11133793 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 22
Study 9335674 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 0
Study 9335674 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials (RCTs)
Number of subjects: 0
Study 8170118 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 word presentations
Number of subjects: 30
Study 8170118 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 word presentations
Number of subjects: 30
Study 8170118 — intervention group
Group type: COMPARATOR
Intervention: 0 word presentations (control condition)
Number of subjects: 30
Study 3064920 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 3064920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29108671 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT‐EP)
Number of subjects: 20
Study 29108671 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 20
Study 26700065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000 IU/day for 3 months)
Number of subjects: 35
Study 26700065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence (interview)
Number of subjects: 510
Study 24853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence (computer-assisted self-interview)
Number of subjects: 510
Study 24853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence estimated by pill count
Number of subjects: 510
Study 24853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication possession ratio
Number of subjects: 510
Study 24853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug detection (tenofovir diphosphate or emtricitabine triphosphate)
Number of subjects: 510
Study 22476832 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulator (LapVR™)
Number of subjects: 44
Study 22476832 — intervention group
Group type: COMPARATOR
Intervention: Video Trainer (VT)
Number of subjects: 44
Study 22476832 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover assessment (LapVR™ to VT and vice versa)
Number of subjects: 44
Study 20575685 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCNL
Number of subjects: 50
Study 20575685 — intervention group
Group type: COMPARATOR
Intervention: PCNL
Number of subjects: 50
Study 18842793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA group (1% DHA)
Number of subjects: 115
Study 18842793 — intervention group
Group type: COMPARATOR
Intervention: Control group (approximately 0.3% DHA)
Number of subjects: 115
Study 16389917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric adjustment techniques for binary covariates
Number of subjects: 0
Study 16389917 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two approaches for adjustment
Number of subjects: 0
Study 12055815 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 117
Study 12055815 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 117
Study 10353379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right frontal lesions
Number of subjects: 80
Study 10353379 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right posterior lesions
Number of subjects: 80
Study 10353379 — intervention group
Group type: COMPARATOR
Intervention: Non-brain-damaged patients (controls)
Number of subjects: 80
Study 8556568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms twice daily for 2 weeks
Number of subjects: 24
Study 8556568 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 24
Study 1971216 — intervention group
Group type: EXPERIMENTAL
Intervention: 443C81 (synthetic enkephalin)
Number of subjects: 12
Study 1971216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipipanone (10 mg, oral)
Number of subjects: 12
Study 1971216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1971216 — intervention group
Group type: EXPERIMENTAL
Intervention: 443C81
Number of subjects: 12
Study 1971216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipipanone
Number of subjects: 12
Study 1971216 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (443C81 and dipipanone)
Number of subjects: 12
Study 7004809 — intervention group
Group type: EXPERIMENTAL
Intervention: Portacaval anastomosis (PCA)
Number of subjects: 90
Study 7004809 — intervention group
Group type: COMPARATOR
Intervention: Unoperated control subjects
Number of subjects: 90
Study 29124951 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational health promotion intervention adapted for persons with SMI
Number of subjects: 20
Study 28922226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 80% oxygen
Number of subjects: 25
Study 28922226 — intervention group
Group type: COMPARATOR
Intervention: Inhalation of 30% oxygen
Number of subjects: 25
Study 25587804 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC training tailored by a low RPE (RPE between 9 and 11)
Number of subjects: 42
Study 25587804 — intervention group
Group type: COMPARATOR
Intervention: CON training tailored by heart rate at the first ventilatory threshold
Number of subjects: 42
Study 25587804 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC training
Number of subjects: 42
Study 25587804 — intervention group
Group type: COMPARATOR
Intervention: CON training
Number of subjects: 42
Study 24719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg)
Number of subjects: 40
Study 24719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy (AT)
Number of subjects: 40
Study 24719126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intracoronary abciximab and aspiration thrombectomy
Number of subjects: 40
Study 22387713 — intervention group
Group type: EXPERIMENTAL
Intervention: FASTED (24h fasting)
Number of subjects: 15
Study 22387713 — intervention group
Group type: COMPARATOR
Intervention: FED (baseline)
Number of subjects: 15
Study 19620075 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with butorphanol
Number of subjects: 60
Study 19620075 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine
Number of subjects: 60
Study 16710430 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral buckling (group 1)
Number of subjects: 43
Study 16710430 — intervention group
Group type: COMPARATOR
Intervention: Pars plana vitrectomy (PPV) (group 2)
Number of subjects: 43
Study 15364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (IV bolus of 180 microg/kg body weight followed by continuous infusion of 2 microg/kg/min)
Number of subjects: 356
Study 15364776 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 356
Study 11216965 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily
Number of subjects: 43
Study 11216965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10513460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 10 mg
Number of subjects: 29
Study 10513460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 15 mg
Number of subjects: 29
Study 10513460 — intervention group
Group type: EXPERIMENTAL
Intervention: Adderall 20 mg
Number of subjects: 29
Study 10513460 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 29
Study 10513460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 8078528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group, 153 subjects)
Number of subjects: 301
Study 8078528 — intervention group
Group type: COMPARATOR
Intervention: Usual health care plus social visits (control group, 148 subjects)
Number of subjects: 301
Study 8078528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group)
Number of subjects: 301
Study 2676390 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg/kg)
Number of subjects: 6
Study 2676390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1249566 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant drug treatment (continued medication)
Number of subjects: 72
Study 1249566 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched)
Number of subjects: 72
Study 31233169 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment
Number of subjects: 70
Study 29441886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosolvan® inhalation in addition to conventional treatment
Number of subjects: 80
Study 29441886 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (Control)
Number of subjects: 80
Study 29441886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosolvan® inhalation
Number of subjects: 80
Study 25942443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Valganciclovir (VGCV) 900mg/day
Number of subjects: 161
Study 25942443 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Ganciclovir (GCV) 5mg/kg twice daily
Number of subjects: 161
Study 22648280 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated soldier patrol (SP) at 42°C, 9% relative humidity for 2.5 hours with 400 mg ibuprofen
Number of subjects: 13
Study 22648280 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated soldier patrol (SP) at room temperature for 2.5 hours with 400 mg ibuprofen
Number of subjects: 13
Study 22648280 — intervention group
Group type: COMPARATOR
Intervention: Sham soldier patrol (SP)
Number of subjects: 13
Study 21368025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at low intensity
Number of subjects: 0
Study 21368025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) at high intensity
Number of subjects: 0
Study 19090503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 16 mg nightly for 6 months
Number of subjects: 0
Study 19090503 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 6 months
Number of subjects: 0
Study 16373650 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex sonography (CDS)
Number of subjects: 177
Study 16373650 — intervention group
Group type: COMPARATOR
Intervention: Cervical MRI and MRA
Number of subjects: 177
Study 15296703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/d)
Number of subjects: 19768
Study 11253266 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of acetylsalicylic acid (ASA) daily
Number of subjects: 18790
Study 11253266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering diastolic BP to about 80 mm Hg
Number of subjects: 18790
Study 11253266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790
Study 9349075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure applied
Number of subjects: 50
Study 9349075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure in an upward and backward direction
Number of subjects: 50
Study 9349075 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard technique of cricoid pressure with neck support
Number of subjects: 50
Study 1588361 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated treatment group (cholesterol reduction)
Number of subjects: 0
Study 1588361 — intervention group
Group type: COMPARATOR
Intervention: Simulated placebo group (no cholesterol reduction)
Number of subjects: 0
Study 1588361 — intervention group
Group type: COMPARATOR
Intervention: Observed incidence in LRC‐CPPT
Number of subjects: 0
Study 4002096 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1 g of amoxicillin plus 1 g of probenecid (group 1)
Number of subjects: 92
Study 4002096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of amoxicillin twice a day for two days (group 2)
Number of subjects: 92
Study 4002096 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg of amoxicillin three times a day for seven days (group 3)
Number of subjects: 92
Study 4002096 — intervention group
Group type: COMPARATOR
Intervention: Groups 1 and 2 combined
Number of subjects: 92
Study 31863755 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive protocol consisting of intermittent ventilation of the right lung, restoration of bilateral ventilation, administration of mannitol before unclamping the aorta, and institution of mild hypothermia.
Number of subjects: 469
Study 31863755 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 469
Study 28511588 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety-stimulating product
Number of subjects: 0
Study 28511588 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 0
Study 28511588 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing product
Number of subjects: 0
Study 26712041 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% AP736 formulation (test formulation; n = 24)
Number of subjects: 48
Study 26712041 — intervention group
Group type: COMPARATOR
Intervention: Vehicle formulation (vehicle control; n = 24)
Number of subjects: 48
Study 25399731 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and ARB (telmisartan)
Number of subjects: 486
Study 25399731 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 486
Study 23169180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux combined with intermittent pneumatic compression (IPC)
Number of subjects: 137
Study 23169180 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression (IPC) alone
Number of subjects: 137
Study 19806411 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous tantalum implant
Number of subjects: 101
Study 19806411 — intervention group
Group type: COMPARATOR
Intervention: Autologous local tibial bone graft
Number of subjects: 101
Study 18606612 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI levels >0.01 microg/L
Number of subjects: 1005
Study 15748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U subcutaneously once weekly
Number of subjects: 94
Study 15748464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 15748464 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 94
Study 11870808 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 11870808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10730720 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant treatment (preference)
Number of subjects: 136
Study 10730720 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment (preference)
Number of subjects: 136
Study 9187986 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (Group R, n = 20)
Number of subjects: 40
Study 9187986 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose (Group G, n = 20)
Number of subjects: 40
Study 1440488 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time B-mode ultrasonography for proximal DVT
Number of subjects: 100
Study 1440488 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time B-mode ultrasonography for overall DVT
Number of subjects: 100
Study 2986424 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF 3.3 to 50 micrograms i.v. bolus
Number of subjects: 14
Study 2986424 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF 100 micrograms/h infusion for 2 to 5 hours after a bolus of 50 micrograms hpGRF
Number of subjects: 14
Study 2986424 — intervention group
Group type: EXPERIMENTAL
Intervention: hpGRF 100 micrograms to 14 patients with active acromegaly
Number of subjects: 14
Study 2986424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30768188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis present during hospitalization
Number of subjects: 568
Study 30768188 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-associated deaths
Number of subjects: 568